Pat gets a healthy thumping no-prize for bringing us this story of a new heart drug that's intended for a single race:
In 1997, a new heart failure treatment called BiDil appeared dead on arrival. The Food and Drug Administration rejected the drug, saying that studies supporting it were inconclusive.
Then, proponents of BiDil refocused their strategy. This Thursday, eight years after the drug was rejected for use in the general public, an F.D.A. panel will consider whether BiDil should become the first drug intended for one racial group, in this case, African-Americans.
I do agree race can sometimes be a very vague definition, but (they claim) the data is sound. Of course, any time you enter Americas Great Cultural Minefield, explosions are inevitable. Only time will tell if this helps anyone, regardless of skin color.